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The Trouble with TEFs
The report by Van den Berg et al. (1)
includes updated toxic equivalency factor
(TEF) values for polychlorinated dibenzo-p-
dioxins (PCDDs), dibenzofurans (PCDFs),
and dioxin-like polychlorinated biphenyls
(PCBs) that the authors propose for use in
human, fish, and wildlife risk assessment.
Given certain simplifying assumptions,
TEFs allow one to estimate the toxicity of
mixtures ofthese compounds by the simple
addition of compound-specific contribu-
tions, expressed in terms of equivalently
toxic concentrations (TEQs) of 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), the
most potent ofthe known aryl hydrocarbon
(Ah) receptor ligands.
Van den Berg et al. (1) describe each
TEF as "an order ofmagnitude estimate of
the toxicity of a compound relative to
TCDD" that was "derived by a consensus of
experts" (the authors) "using careful scientif-
ic judgment after considering all available
scientific data." 'While their report reviews
several sources of uncertainty "that could
compromise the TEF concept," including
"nonadditive interactions, differences in
shape of the dose-response curve, and
species responsiveness," itconcludes that
it is unlikely for the use ofthis additive model to
result in a great deal of error in predicting the
concentrations ofTCDD TEQs or responses at
environmentally relevant levels due to nonaddi-
tive interactions.
The phrase "unlikely to result in a great
deal oferror" is the only uncertainty charac-
terization that Van den Berg et al. (1) pro-
vide to readers. Clearly, it is an inadequate
characterization ofthe uncertainty that TEFs
arelikely to introduce into human orecolog-
ic risk assessments. Any adequate TEFs
uncertaintycharacterization shouldminimal-
ly include a) explicit enumeration ofeach
relative potency estimate (REP) used in the
determination ofa TEF, along with explicit,
quantitative estimates of the uncertainty
associated with each such REP; b) explicit,
quantitative estimates of the uncertainty
associated with each TEF; and c) explicit,
quantitative estimates ofthe extent to which
the various end point-specific dose-response
curves depart from strict parallelism with
each other and with the classic rectangular
hyperbola that relates Ah receptoroccupancy
to the freeligand concentration.
Except in a few cases where TEFs were
derived from a single REP (e.g., the bird
TEFs for the PCBs 105, 126, 156, 157,
167, and 169), the end point-specific REP
data that were considered by Van den Berg
et al. (1) in deriving any given TEF are not
provided in their report (although the data-
base is said to be available in computerized
form). The authors mention several different
methods that were used to determine REPs:
a) as reported by the original investigators; b)
as calculated by "comparing dose-response
curves"; c) by using "linear interpolation of
log-doses;" and a) as determined
from ratios of medium effective dose (ED50),
median lethal dose (LD50), and median effective
concentration (EC50) values; tumor promotion
indexes; dissociation constant (Kd) values for Ah
receptor binding; or directly estimated from the
graphs presented.
These methods are clearly not equivalent;
therefore, they are likely to have substan-
tially different degrees ofuncertainty associ-
ated with them. We do not know from the
report which ofthese methods was used for
each REP, and most importantly, explicit
quantitative estimates of the uncertainty
associated with each REP are also not pro-
vided. While statistical methodology for
generating such estimates has been
employed routinely in the pharmacology
literature for many years (2), Van den Berg
et al. (1) appear to have treated the REPs
employed in deriving their TEFs as ifthey
were known without error.
Quantitative estimates ofthe uncertainty
associated with each TEF are similarly
absent from the report ofVan den Berg and
colleagues (1). Even the range ofconsidered
REP values, which provides a very coarse
index of uncertainty, is rarely reported.
When it is (e.g., for the bird TEFs for PCBs
77 and 81), the range is rather large (500-
fold in these cases). This is true also for some
of the PCB TEFs that were not changed
from previously recommended values (3).
For example, the mammalian TEF of
0.0005 for PCB 156 wasderived byAhlborg
et al. (3) from in vivo study REPs that
ranged over more than three orders ofmag-
nitude (see their Figure 1). For PCB 169,
the in vivo REPs considered by Ahlborg et
al. ranged over more than four orders of
magnitude! How can a single TEF value
adequately characterize this wide range of
end point-specific responses without some
associated estimate ofuncertainty? Clearly, it
cannot. In a similar fashion, a single TEQ
concentration calculated with TEFs cannot
adequately characterize possible human or
environmental responses without some asso-
ciated estimate ofuncertainty.
It is also important to recognize that
TEFs derived from dose-response data near
the large doses that induce one-half of the
maximal response may have little, if any,
relevance to responses that may occur at far
lower human orenvironmental background
exposures. For high-dose TEFs to be truly
valid at lower doses, the dose-response
curves for the various end points ofconcern
must be parallel to each other and parallel
also to the dose-response curve for Ah
receptor occupancy. If this were not the
case, alignment of the various curves to
agree at a TEF-adjusted EC50 would guar-
antee disagreement elsewhere, and the dis-
agreement would grow as the distance from
the adjusted EC50 increased. Thus, paral-
lelism of dose response across end points
and Ah receptor ligands is necessary for the
TEFs concept to be valid; yet there is much
evidence that parallelism does not hold,
even among the simplest and best-under-
stood responses such as hepatic enzyme
induction (4).
Finally, it must be noted that quantita-
tive scientific estimates of the uncertainty
associated with TEFs can only be devel-
oped if the TEFs themselves are explicitly
defined. Clearly, the reported TEFs repre-
sent some kind ofa weighted average ofthe
considered REPs, but the weights employed
by Van den Berg et al. (1) are unknown
and subjective, at least in part, because they
were never made explicit. This approach
falls far short ofproviding the solid, scien-
tific foundation that is now required in
transparent, defensible human health and
environmental risk assessments. Explicit
consideration of the numerous uncertain-
ties associated with the TEF approach
would be a big step in the right direction. It
may well be that species-, end point-, and
dose-specific TEFs will be required for the
TEF concept to prove truly useful in a risk
assessment context (5).
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van Leeuwen's Response
In our paper, "Toxic Equivalency Factors
(TEFs) for PCBs, PCDDs, PCDFs for
Humans and Wildlife" (1), we described the
results of a World Health Organization
(WHO) working group that evaluated the
existing TEFs for human risk assessment and
derived consensus TEFs for fish and birds.
Starr et al. comment on the approach
taken for the derivation of TEFs as
described in our paper (1) and criticize the
inadequate characterization of the uncer-
tainty ofthe TEFs. They state that the fol-
lowing sentence is the only uncertainty
characterization:
... it is unlikely for the use ofthis additive model
to result in a great deal oferror in predicting the
concentrations of TCDD TEQs or responses at
environmentally relevant levels due to nonaddi-
tive interactions.
In addition, they request explicit quantita-
tive estimates on the uncertainty in each
REP value, each TEF, and on the deviation
from parallelism for the different end points.
Their first statement is incorrect. In the
paper we clearly stated that the TEFs that
were derived are "an order of magnitude
estimate." This is a clear illustration of the
overall uncertainty in TEF values based on
the differences in outcomes ofthe different
end points and the variation in available
data for the different congeners. In addi-
tion, Starr et al. misinterpreted the sentence
quoted above. This sentence is based on the
opinion ofVan den Berg et al. (1) that the
use of an additive model in the TEF
approach, in contrast to including nonad-
ditive (synergistic or antagonistic) effects,
does not result "in a great deal oferror."
Providing a quantitative estimate of the
uncertainty of the individual REPs, as
requested by Starr et al., is often not possible.
Uncertainty in no-observed-(adverse)-effect
levels [or lowest-observed-(adverse)-effect lev-
els] or EC50 is usually not given in the stud-
ies used by the WHO working group.
Therefore, a more qualitative, tiered
approach was chosen to select the REPvalues
in which we had greatest confidence, and not
because we believe they are "without error."
This weighted procedure is clearly outlined
in the original paper. For those scientists who
want to address the variation in REP values
in more detail, the database containing all the
information that was used in the derivation
ofTEFs is available on request. In their com-
ments, Starr et al. suggestively stated that
"the database is said to be available." The
database was available directly after the
WHO TEF meeting that was held in June
1997. Requests were received from several
people, and all ofthem received the data.
Regarding their comment on the
requirement of "parallelism of dose-
response curves across end points" Starr et
al. apparently failed to understand that the
cascade of events following binding to the
Ah receptor is different for each end point,
which might thus result in different
dose-response curves. Basic pharmacology
and endocrinology have shown that multi-
ple responses mediated by the same recep-
tor mechanism do not have to have parallel
dose-response curves because binding to a
receptor is but the first step in the cascade
of responses. Thus, per definition, the
dose-response curves for different health
end points cannot be expected to be paral-
lel. This is one of the inherent uncertain-
ties in the derivation of TEFs, but this is
well recognized and covered adequately by
Van den Berg et al. (1). Parallel
dose-response curves are required for dif-
ferent congeners examining the same
response, but this has been amply demon-
strated in the literature for various dioxins,
furans, and PCBs for various responses,
and it was adequately covered by Van den
Berg et al.
Where Starr et al. criticize the current
approach and advocate the derivation of
"species-, end point-, and dose-specific
TEFs," it should be mentioned that the
lack of information on dose-response rela-
tionships for all congeners, all end points/
responses, and all species was just one of
the reasons to develop the TEF methodolo-
gy. It is highly unlikely that we could test
all the congeners for all relevant end points
and all species, including humans.
Finally, the TEF approach is a risk
assessment tool; it was not developed to
produce precise estimates of risk, but to
approximate the toxic potency ofexposure
to a mixture ofdioxin-like compounds. As
such, it appears to work remarkably well. A
large number ofstudies published in peer-
reviewed literature have demonstrated a
statistically highly significant correlation
between TEQ levels in complex mixtures,
derived by making use of TEFs, and pre-
dicted health outcomes in different animal
species. An overview of this can be found
in a series of articles in Human and
Ecological Risk Assessment, Volume 5
(1999), in which several of these studies
have been cited. Thus, we conclude that
although the TEF approach might not be
perfect because of its inherent uncertain-
ties, no valid alternative for risk assessment
purposes currently exists.
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Safe Food: Should We Be
Afraid?
I would like to comment on the article
"Safe Food: An All-consuming Issue" (1). I
consider this article to be scaremongering.
Scaremongering, a very real and increasingly
dangerous problem, often with total disre-
gard to the truth, has become a major, and
obviously profitable, growth industry
wherein "nonprofit" organizations and vari-
ous individuals prosper at the expense ofthe
credulous public. Just how credulous can
the public be? This week I had a vivid
example when my wife of 55 years, on the
basis of a recent article, told me she would
no longer serve me meat products such as
salami and summer sausage, which I have
been happily consuming for most ofmy life!
True, meat contamination by such
organisms as Salmonella and new virulent
mutant strains of Escherichia coli kills many
people every year, usually in fresh ground
meat. These deaths are totally avoidable by
the appropriate use of irradiation. I have
worked with or studied food irradiation since
1950 and know that, worldwide, hundreds
ofinvestigations have shown food irradiation
to be totallyeffective andcompletelysafe.
Yet Schmidt cites Food and Water mere-
ly as a "nonprofit advocacy organization."
How could he! This is the organization that
spends quite extraordinary amounts of
money proclaiming that anyone who eats
irradiated foods is likely to have severely
deformed children (among other horrors).
I could fill many pages with accounts of
encounters with some these dangerous
frauds, and over the years I have written
several articles on the topic ofscaremonger-
ing in the food industry (2-4).
I am old (81) and long retired (since
1982), and I profoundly hope that some-
time soon a publication such as EHP will
give the same concern to this scandal as you
would to any other virulent epidemic.
Thank you for this chance to blow off
some steam.
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